The Minnesota State Senate has passed a resolution designating May 4 to 10, 2025, as Tardive Dyskinesia Awareness Week. This initiative aims to raise awareness about tardive dyskinesia (TD), a movement disorder that can occur in individuals treated with dopamine receptor blocking agents (DRBAs), such as antipsychotic medications. TD affects approximately 800,000 people in the U.S., with a significant number remaining undiagnosed. The resolution emphasizes the importance of recognizing the symptoms and impacts of TD, as even mild cases can lead to physical, social, and emotional challenges.

The resolution also highlights the necessity for regular monitoring and screening for TD among patients using DRBAs, as recommended by the American Psychiatric Association. Furthermore, it notes that clinical research has resulted in FDA-approved treatments for adults with TD. By designating this week, the Minnesota State Senate encourages residents to educate themselves and others about tardive dyskinesia, thereby fostering greater awareness within both the public and medical communities.